Literature DB >> 30190866

Can histone proteins promote the growth of melanoma?

Chiara Vardabasso1, Emily Bernstein1.   

Abstract

Entities:  

Keywords:  BET; BRD2; H2A.Z; chromatin; epigenetics; histone variants; macroH2A; melanoma

Year:  2016        PMID： 30190866      PMCID： PMC6094619          DOI： 10.2217/mmt.15.35

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  20 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

2.  BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Authors:  Miguel F Segura; Bárbara Fontanals-Cirera; Avital Gaziel-Sovran; María V Guijarro; Doug Hanniford; Guangtao Zhang; Pilar González-Gomez; Marta Morante; Luz Jubierre; Weijia Zhang; Farbod Darvishian; Michael Ohlmeyer; Iman Osman; Ming-Ming Zhou; Eva Hernando
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

Review 3.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

4.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.

Authors:  Daniel Zingg; Julien Debbache; Simon M Schaefer; Eylul Tuncer; Sandra C Frommel; Phil Cheng; Natalia Arenas-Ramirez; Jessica Haeusel; Yudong Zhang; Mario Bonalli; Michael T McCabe; Caretha L Creasy; Mitchell P Levesque; Onur Boyman; Raffaella Santoro; Olga Shakhova; Reinhard Dummer; Lukas Sommer
Journal:  Nat Commun       Date:  2015-01-22       Impact factor: 14.919

7.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

8.  Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.

Authors:  Chiara Vardabasso; Alexandre Gaspar-Maia; Dan Hasson; Sebastian Pünzeler; David Valle-Garcia; Tobias Straub; Eva C Keilhauer; Thomas Strub; Joanna Dong; Taniya Panda; Chi-Yeh Chung; Jonathan L Yao; Rajendra Singh; Miguel F Segura; Barbara Fontanals-Cirera; Amit Verma; Matthias Mann; Eva Hernando; Sandra B Hake; Emily Bernstein
Journal:  Mol Cell       Date:  2015-06-04       Impact factor: 17.970

9.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

10.  Decreased expression of the chromatin remodeler ATRX associates with melanoma progression.

Authors:  Zulekha A Qadeer; Sara Harcharik; David Valle-Garcia; Chen Chen; Miriam B Birge; Chiara Vardabasso; Luis F Duarte; Emily Bernstein
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.